Eledon pharmaceuticals announces update on development strategy for at-1501 in renal transplantation

Irvine, calif., april 26, 2021 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (als), today announced an updated development strategy for at-1501 in renal transplantation.
ELDN Ratings Summary
ELDN Quant Ranking